Ex-vivo treatment of T-cells with IFN-λ
The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-λ). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-λ and returned to the patient. The present invention also provides a method of ex vivo treatment, in conjunction with co-administration of IFN-λ.
1. A method of ex vivo treatment of T-cells, comprising the steps:
(a) obtaining peripheral blood from a human subject suffering from asthma;
(b) isolating mononuclear cells from said peripheral blood;
(c) purifying T-cells from said isolated mononuclear cells;
(d) exposing said purified T-cells to IFN-λ; and
(e) administering said exposed cells to said human subject,
wherein said IFN-λ is present in an amount sufficient to inhibit stimulus-induced cytokine release, and
wherein said stimulus is selected from the group consisting of Concanavalin A and anti-CD2/3/28 beads and said cytokine is at least one compound selected from the group consisting of IL-4 and IL-5.
2. The method of claim 1 , wherein said purified T-cells are naïve T-cells.
3. The method of claim 1 , wherein said purified T-cells are memory T-cells.
4. The method of claim 1 , wherein said IFN-λ is at least one compound selected from the group consisting of IFN-λ1, IFN-λ2, and IFN-λ3.
5. The method of claim 1 , wherein said amount is in the range about 1 ng/mL to about 200 μg/mL.
6. The method of claim 1 , wherein said amount is in the range of about 100 ng/mL to about 10 μg/mL.
7. The method of claim 1 , wherein said exposing step is performed for about 1 hour to about 24 hours.
8. The method of claim 1 , wherein said exposing step is performed for about 6 hours to about 12 hours.
9. The method of claim 1 , wherein said asthma is virus-induced or allergen-induced.
10. The method of claim 1 , wherein said mononuclear cells are in the range of about 1×10 7 cells to about 1×10 9 cells.
11. The method of claim 1 , wherein said mononuclear cells are about 1×10 8 cells.
12. The method of claim 1 , further comprising the step of repeating the step (a) through step (e).
13. The method of claim 1 , further comprising the step (f) of administering a composition comprising IFN-λ to the human subject.
14. The method of claim 13 , wherein said IFN-λ composition is administered nasally, intravenously, or orally.
15. The method of claim 13 , wherein said step (f) is performed simultaneously or sequentially with step (e).